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Summary 
 
 
  
 
Cannabidiol (CBD) is one of the naturally occurring cannabinoids found in cannabis plants. It 
is a 21-carbon terpenophenolic compound which is formed following decarboxylation from a 
cannabidiolic acid precursor, although it can also be produced synthetically.  
 
CBD can be converted to tetrahydrocannabinol (THC) under experimental conditions; 
however, this does not appear to occur to any significant effect in patients undergoing CBD 
treatment. 
 
In experimental models of abuse liability, CBD appears to have little effect on conditioned 
place preference or intracranial self-stimulation. In an animal drug discrimination model CBD 
failed to substitute for THC. In humans, CBD exhibits no effects indicative of any abuse or 
dependence potential.  
CBD has been demonstrated as an effective treatment of epilepsy in several clinical trials, with 
one pure CBD product (Epidiolex®) currently in Phase III trials. There is also preliminary 
evidence that CBD may be a useful treatment for a number of other medical conditions.  
There is unsanctioned medical use of CBD based products with oils, supplements, gums, and 
high concentration extracts available online for the treatment of many ailments.  
CBD is generally well tolerated with a good safety profile. Reported adverse effects may be as 
a result of drug-drug interactions between CBD and patients’ existing medications.  
Several countries have modified their national controls to accommodate CBD as a medicinal 
product.  
To date, there is no evidence of recreational use of CBD or any public health related problems 
associated with the use of pure CBD. 
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1. Substance identification  
A. International Nonproprietary Name (INN) 
Cannabidiol 
B. Chemical Abstract Service (CAS) Registry Number 
13956-29-1 [1] 
C. Other Chemical Names 
CBD; 
2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-
benzenediol; [2] 
D. Trade Names 
 Epidiolex® (in development) 
Arvisol® (in development)  
E. Street Names 
No data available 
F. Physical Appearance 
A crystalline solid [2] 
G. WHO Review History 
Cannabidiol has not been previously pre-reviewed or critically reviewed by 
the WHO Expert Committee on Drug Dependence (ECDD). The current 
review is based on the recommendation from the 38th ECDD that pre-review 
documentation on cannabis-related substances, including cannabidiol, be 
prepared and evaluated at a subsequent committee meeting[3].  
 
2. Chemistry 
A. Chemical Name 
IUPAC Name: 2-[(6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-
yl]-5-pentylbenzene-1,3-diol 
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B. Chemical Structure 
 
Molecular Formula: C21H30O2 
Molecular Weight: 314.469 g/mol 
  
C. Stereoisomers 
Cannabidiol (CBD) is normally taken to refer to the naturally occurring (-)-
enantiomer. (+) CBD has been synthesised [4], but has received little attention. 
 (+) CBD has been shown to have modest affinity at CB1 and CB2 receptors 
unlike (-) CBD ((+)-CBD Ki= 0.84 µM at CB1), whereas both compounds 
inhibited anandamide hydrolysis and were agonists at the vanilloid type 1 
(VR1) receptor at which capsaicin acts. [5] The (+)-CBD isomer was more 
active than the (-)-CBD-isomer as an anticonvulsant agent in a mouse seizure 
model. [6] However, to date, there is no substantive evidence as to whether 
(+)-CBD is likely to cause THC-like psychoactive effects.  
D. Methods and Ease of Illicit Manufacturing 
Synthesis of CBD in vitro: 
Synthetic routes are available for the production of CBD, but some of the 
published methods yield only small amounts of CBD. The two most efficient 
routes are: 
 
1) The condensation of (+)-e-mentha-diene-l-01 with olivetol in the presence 
of weak acids (oxalic, picric or maleic acid). The isomer obtained in this 
reaction may be converted to CBD with BF3-etherate by a retro-Friedel-
Crafts reaction, followed by recombination. However, with this reagent the 
reaction proceeds further causing cyclisation of CBD to delta-1-THC and 
iso-THC [7] 
 
2) A one step reaction for CBD synthesis utilizes boron trifluoride (BF3)-
etherate on alumina as condensing reagent in the reaction of (+)-e-mentha-
diene-l-01 with olivetol on a 0.8mmol scale (refer to Figure 1). This results 
in CBD as the major product, with 55% yield as chromatographically pure 
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oil or 41% yield as crystalline material. On a 100mmol scale, the yields 
were 46% as an oil, and 37% as crystalline material. [8] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Synthesis of CBD with boron trifluoride (BF3)-etherate taken 
from Mechoulam et al 2002 [9] 
 
Synthesis of CBD in plants:  
 
Cannabis cultivars range from those grown to produce cannabis for 
recreational purposes to those produced in order to use hemp fibre derived 
from the stems of the plant. In cultivars utilized for recreational purposes, the 
quantity of THC exceeds that of CBD in the dried female inflorescences used 
for smoking and oral administration. Hemp cultivars produce substantially less 
THC and higher levels of CBD. [10] Unsanctioned production of cannabis 
cultivars with high CBD levels does occur for purposes of medical treatment 
rather than recreational use (refer to Section 13).  
 
In plants, THC and CBD are derived from their acidic precursors Δ9-
tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA) (refer to 
Figure 2).  THCA and CBDA are both derived from cannabigerolic acid 
(CBGA).  The final step differs, with THCA synthase and CBDA synthase 
producing THCA or CBDA, respectively, from CBGA. Subsequent 
decarboxylation of THCA and CBDA via light exposure, heating, or aging, 
results in THC or CBD.[10-12] 
 
CBD (major product) 
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Figure 2: Biogenesis of THC and CBD adapted from Taura et al. (2007)  
THCA synthase and CBDA synthase catalyze oxidative cyclization of the 
monoterpene moiety of CBGA to form THCA and CBDA, respectively. THC 
and CBD are generated from THCA and CBDA by non‐enzymatic 
decarboxylation. [11] 
 
In addition to genetic characteristics, cultivated plants are influenced by 
environmental conditions and production technology during their life cycle. A 
study evaluating the effects of ambient temperature and humidity, soil 
temperature and precipitation on the content of THC and CBD in industrial 
hemp noted that these agroclimatic conditions have differing effects on THC 
and CBD. For example, CBD content is positively affected by soil temperature 
and ambient temperature, but negatively influenced by precipitation [13]  
 
E. Chemical Properties 
Melting point: 62-63°C 
Solubility: approx. 23.6 mg/mL in DSMO and ethanol [14] 
 
F. Identification and Analysis  
There are a number of published methods for the analytical detection of CBD 
in various biological samples. For example,  
▪ spectrophotometric determination [15]; 
▪ liquid chromatography–tandem mass spectrometry (LC–MS/MS) 
detection of CBD in whole blood [16, 17] samples; 
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▪ high performance (HP) LC-MS/MS methods for CBD detection in hair 
[18], urine [19] and plasma [20] samples; 
▪ gas chromatography mass spectrometry (GC-MS) detection of CBD in 
hair [21, 22], oral [23] and plasma [24] samples;  
▪ 2-dimensional-GC-MS methods for detection in oral fluid [25], plasma 
[26] and post mortem blood samples [27]. 
 
3. Ease of Convertibility Into Controlled Substances 
There is some evidence that CBD can be converted to tetrahydrocannabinol (THC), a 
Schedule 1 substance under the United Nations Convention on Psychotropic 
Substances 1971. Two main methods have been reported and there has been some 
investigation into whether this occurs spontaneously in vivo. 
 
Conversion in the laboratory 
 
Under experimental conditions, it has been demonstrated that heating CBD in 
solutions of some acids catalyses cyclizations within the CBD molecule resulting in 
delta-9-THC [28].  Gaoni and Mechoulam have published several papers regarding 
methods of converting CBD to other cannabinoids including THC, however the yields 
vary and purity is unclear. [9] 
 
A version of this method has been reported on a drug user forum. It suggests 
dissolving CBD in sulphuric acid/acetic acid and leaving it for anywhere from 3 hours 
to 3 days to obtain delta-9-THC and delta-8-THC. After 3 hours, the author states that 
CBD has been converted into 52% delta-9-THC and 2% delta-8-THC [31]. 
 
A patent (US 2004/0143126 A1) on the conversion of CBD to delta-9-THC details a 
method involving the addition of BF3Et2O (50 µl), under nitrogen atmosphere, to an 
ice cold solution of CBD (300 mg) in dry methylene chloride (15 ml). The solution is 
stirred at 0° C for 1 hour, followed by the addition of saturated aqueous solution of 
NaHCO3 (2 ml) until the red colour fades. The organic layer is removed, washed with 
water, dried over MgSO4 and evaporated. The composition of the oil obtained 
(determined by HPLC) is: trans-delta8-isoTHC 27%, delta-9-THC 66.7%. The oil is 
then chromatographed on silica gel column (20 g) and eluted with petroleum ether 
followed by graded mixtures, up to 2:98 of ether in petroleum ether. The first fraction 
eluted was the delta8-isoTHC (30 mg, 9.5%) followed by a mixture of delta8-iso THC 
and delta-9-THC (100 mg). The last compound to be eluted was the delta-9-THC (172 
mg, 57%). The purity of delta-9-THC (as determined by HPLC) is 98.7%.  [29] 
  
Spontaneous conversion 
 
It has been proposed that the conversion of CBD to delta-9-THC in the presence of 
acid could occur in the human gut. Such conversion could be of importance if CBD is 
administered orally. Two in vitro studies have used simulated gastric fluid to 
demonstrate the potential for this conversion.  The first reported the formation of 
analytically confirmed delta-9-THC and delta-8-THC when CBD was exposed to 
simulated gastric fluid without enzymes at 37ºC. The authors concluded that that the 
acidic environment during normal gastrointestinal transit could expose orally CBD-
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treated patients to levels of THC and other psychoactive cannabinoids that may 
exceed the threshold for a physiological response. [30]  The second in vitro study also 
reported the formation of delta-9-THC along with other cannabinoid products in 
artificial gastric juice without pepsin. The conversion rate of CBD to THC was only 
2.9%. [31] 
 
The predictive value of these in vitro studies for humans administering cannabidiol 
orally has been questioned as simulated gastric ﬂuid does not exactly replicate 
physiological conditions in the stomach. [32] Furthermore, spontaneous conversion of 
CBD to delta-9-THC has not been demonstrated in humans undergoing CBD 
treatment. For example, in a six week clinical study in Huntington’s disease patients 
who were administered CBD 700 mg/day, the CBD average plasma concentration 
range was 5.9-11.2 ng/mL with no delta-9-THC detected. [33] 
 
In humans, THC effects are characterised by impairment of psychomotor and 
cognitive performance, and a range of physical effects including increased heart rate 
and dry mouth. In general, clinical studies have reported that even high doses of oral 
CBD do not cause the those effects that are characteristic for THC and for cannabis 
rich in THC.[34] For example, in a study of healthy volunteers administered 200mg 
oral CBD, CBD did not produce any impairments of motor or psychomotor 
performance.[35] A number of other studies involving high doses of CBD were 
recently summarized by Grotenhermen et al.[34]; they concluded that high doses of 
oral CBD consistently fail to demonstrate significant effects or demonstrate effects 
opposite to those of THC. 
 
While it has been suggested that further large-scale human studies are needed to 
explore the gastric conversion and potential THC-like side effects following oral CBD 
administration [36], it is very unlikely that oral cannabidiol will be shown to result in 
THC concentrations sufficient to induce any meaningful effects. 
 
4. General Pharmacology 
A. Routes of administration and dosage 
Currently there are no approved marketed pure CBD medicinal products, 
although two are in development (refer to Section 11).   
 
In clinical trials and research studies, CBD is generally administered orally as 
either a capsule, or dissolved in an oil solution (e.g. olive or sesame oil). It can 
also be administered through sublingual or intranasal routes. A wide range of 
oral doses have been reported in the literature, with most from 100-
800mg/day. [37] 
 
B. Pharmacokinetics 
Oral delivery of an oil-based capsule formulation of CBD has been assessed in 
humans. Probably due to its poor aqueous solubility, the absorption of CBD 
from the gastrointestinal tract is erratic, and the resulting pharmacokinetic 
profile is variable. Bioavailability from oral delivery was estimated to be 6% 
due to significant first-pass metabolism.[38] In healthy male volunteers, the 
mean±SD whole blood levels of CBD at 1, 2 and 3 hours after administration 
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of 600mg oral CBD  were reported to be 0.36 (0.64) ng/mL, 1.62 (2.98) ng/mL 
and 3.4 (6.42) ng/mL, respectively. [39] Aerosolized CBD has been reported 
to yield rapid peak plasma concentrations in 5–10 minutes and higher 
bioavailability than oral administration.  
 
CBD is rapidly distributed into the tissues with a high volume of distribution 
of ~32L/kg. Like THC, CBD may preferentially accumulate in adipose tissues 
due to its high lipophilicity. [37, 40]   
 
CBD is extensively metabolised in the liver. The primary route is 
hydroxylation to 7-OH-CBD which is then metabolised further resulting in a 
number of metabolites that are excreted in faeces and urine.[38] A study in 
human liver microsomes (HLMs) demonstrated that CBD was metabolized by 
pooled HLMs to eight monohydroxylated metabolites (6α-OH-, 6β-OH-,7-
OH-, 1”-OH-, 2”-OH-, 3”-OH-, 4”-OH-, and 5”-OH-CBDs). Among these 
metabolites, 6α-OH-, 6β-OH-, 7-OH-, and 4”-OH-CBDs were the major ones. 
Seven recombinant human CYP enzymes were identified as capable of 
metabolising CBD: CYP1A1, CYP1A2, CYP2C9, CYP2C19, CYP2D6, 
CYP3A4, and CYP3A5. The two main isoforms involved are CYP3A4 and 
CYP2C19. [41] 
 
In a number of studies, CBD has been shown to inhibit CYP isozymes in vitro, 
but it is not clear that this occurs at concentrations achieved with doses used 
clinically.   
C. Pharmacodynamics 
There are two main cannabinoid (CB) receptors, CB1 which is primarily 
located in the central nervous system with some expression in peripheral 
tissues and CB2 receptors, which can be found in the periphery on cells with 
immune function and in the gastrointestinal tract and at low densities in the 
central nervous system.  
 
CBD does not appear to act directly at CB1 receptors, with a number of studies 
reporting that there is no measurable response in binding assays. In studies 
examining potential agonist effects at CB1 receptors, most find no effect, with 
one report of a weak agonist and one of a weak antagonist effect, each at high 
concentrations (>10uM). CBD also shows low affinity at CB2 receptors. [42]  
 
Across a range of measures in humans and animals, CBD had been shown to 
have very different effects from those of THC. In mice, CBD failed to produce 
the behavioral characteristics (e.g. suppression of locomotor activity, 
hypothermia, antinociception) associated with CB1 activation, whereas THC 
generated all of the effects which occur when CB1 is activated. [43, 44]  
Neuroimaging studies in humans and animals have shown that CBD has 
effects which are generally opposite to those of THC.[45] In contrast to THC, 
CBD has no effect on heart rate or blood pressure under normal conditions, but 
in animal models of stress it reduces heart rate and blood pressure.[46] Other 
differences between THC and CBD are discussed below. 
 
Some studies have shown that CBD may reduce or antagonize some of the 
effects of THC. The mechanism for this is unclear, with some suggesting that 
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it may be a weak CB1 antagonist. Recent evidence suggests that it may be a 
negative allosteric modulator of the CB1 receptor, thereby acting as a non-
competitive antagonist of the actions of THC and other CB1 agonists.[42, 47] 
 
CBD may also interact with the endocannabinoid system through indirect 
mechanisms such as enhanced action of the endogenous cannabinoid ligand 
anandamide. This results from blockade of anandamide reuptake and the 
inhibition of its enzymatic degradation. [5, 9, 41]  
 
CBD has been shown to modulate several non-endocannabinoid signaling 
systems. It is not clear which, if any, of these mechanisms are responsible for 
any of CBD’s potential clinical or other effects. Some of these mechanism 
include [48]: 
• Inhibition of adenosine uptake, possibly resulting in indirect 
agonist activity at adenosine receptors.  
• Enhanced activity at the 5-HT1a receptor.  
• Enhanced  activity at glycine receptor subtypes  
• Blockade of the orphan G-protein-coupled receptor GPR55  
 
5. Toxicology 
The potential toxic effects of CBD have been extensively reviewed [49] with a recent 
update of the literature. [50] In general, CBD has been found to have relatively low 
toxicity, although not all potential effects have been explored. The following are some 
of the relevant findings to date from in vitro and animal studies: 
• CBD affects growth of tumoral cell lines, but has no effect in most non-
tumour cells. However, a pro-apoptotic effect has been observed in 
lymphocytes. 
• It has no effect on embryonic development (limited research) 
• Evidence on potential hormonal changes is mixed, with some evidence of 
possible effects and other studies suggesting no effect, depending on the 
method used and the particular hormone 
• It has no effect on a wide range of physiological and biochemical parameters 
or significant effects on animal behaviour unless extremely high doses are 
administered (eg, in excess of 150 mg/kg iv as an acute dose or in excess of 
30 mg/kg orally daily for 90 days in monkeys) 
• Effects on the immune system are unclear; there is evidence of immune 
suppression at higher concentrations, but immune stimulation may occur at 
lower concentrations. 
• There is potential for CBD to be associated with drug interactions through 
inhibition of some cytochrome P450 enzymes, but it is not yet clear whether 
these effects occur at physiological concentrations.  
 
6. Adverse Reactions in Humans 
As noted above, CBD does not produce the effects that are typically seen with 
cannabinoids such as THC. It also failed to produce significant effects in a human 
study of abuse potential discussed below.[39] Across a number of controlled and open 
label trials CBD of the potential therapeutic effects of CBD it is generally well 
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tolerated, with a good safety profile. [37, 50] Clinical trials involving use of CBD for 
treatment of epilepsy will be discussed in Section 9: Therapeutic Applications.  
 
7. Dependence Potential 
A. Animal Studies 
Male mice were injected i.p once a day for 14 days with either CBD (0.1, 1, or 
3mg/kg) or delta-9-THC (1, 3, or 10mg/kg). Tolerance to the effects of THC 
was observed, however no tolerance to CBD at any of the dosages was 
observed. [51] No studies of the physical dependence potential of CBD in 
animals were identified. 
B. Human Studies 
Controlled, human studies regarding the potential physical dependence effects 
(e.g. withdrawal and tolerance) of cannabidiol have not been reported 
 
8. Abuse Potential 
A. Animal Studies 
In male Sprague-Dawley rats, administration of low dose (5 mg/kg) CBD did 
not change the threshold frequency required for intracranial self-stimulation 
(ICSS). However, high dose (10 mg/kg and 20 mg/kg) CBD resulted in an 
elevation of the threshold suggestive of diminished reward activity. This effect 
is opposite to that of drugs of abuse such as cocaine, methamphetamine and 
opioids which lower the threshold.[52]  
 
Increased dopamine release in cells of the mesolimbic ventral tegmental area – 
nucleus accumbens pathway is a common effect characteristic of almost all 
drugs of abuse. While THC has been shown to increase the firing rate of these 
cells, cannabidiol had no effect. [53] 
 
It appears that CBD given alone has little effect on conditioned place 
preference (CPP). For example, Long-Evans rats treated with 10 mg/kg CBD 
showed neither CPP nor CPA.[54] However, rats treated with increasing doses 
of CBD and THC (1, 3, and 10 mg/kg) exhibited a trend towards CPP not seen 
in those given THC alone. [55] The authors attributed this to a 
pharmacokinetic interaction leading to higher THC concentrations rather than 
a change in receptor action. 
 
CBD appears not to exhibit THC-like discriminative stimulus effects. For 
example, in rats trained to discriminate THC from vehicle, CBD did not 
substitute for THC at any dose tested [54]. CBD also failed to substitute for 
THC in pigeons trained to discriminate THC from vehicle. [56]  
B. Human Studies 
While the number of studies is limited, the evidence from well controlled 
human experimental research indicates that CBD is not associated with abuse 
potential. 
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Single dose administration of cannabidiol has been evaluated in healthy 
volunteers using a variety of tests of abuse potential as well as physiological 
effects in a randomised double blind placebo controlled trial.[39] An orally 
administered dose of 600mg of CBD did not differ from placebo on the scales 
of the Addiction Research Centre Inventory, a 16 item Visual Analogue Mood 
Scale, subjective level of intoxication or psychotic symptoms. In contrast, 
THC (10mg oral) administration was associated with subjective intoxication 
and euphoria as well as changes in ARCI scales reflecting sedation and 
hallucinogenic activity. THC also increased psychotic symptoms and anxiety. 
While THC increased heart rate, CBD had no physiological effects. 
 
A randomized, double-blind, within-subject laboratory study was undertaken 
to assess the influence of CBD (0, 200, 400, 800mg, p.o.) pre-treatment on the 
effects of inactive (0.01% THC) and active (5.30–5.80% THC) smoked 
cannabis. Healthy cannabis smokers (n=31) completed eight outpatient 
sessions with CBD administered 90min prior to cannabis administration. 
Under placebo CBD conditions, active cannabis was self-administered by 
significantly more participants and produced significant, time-dependent 
increases in subjective ratings and heart rate relative to inactive cannabis. 
CBD alone produced no significant psychoactive, cardiovascular or other 
effects. Cannabis self-administration, subjective effects, and cannabis ratings 
did not vary as a function of CBD dose relative to placebo capsules. These 
findings suggest that oral CBD does not reduce the reinforcing, physiological, 
or positive subjective effects of smoked cannabis.[57] 
 
The authors of the study then undertook a second analysis of this data to 
examine the abuse liability profile of oral cannabidiol in comparison to oral 
placebo and active smoked cannabis. The results of this analysis demonstrated 
that CBD was placebo-like on all measures (including visual analogue scales, 
psychomotor performance such as the digit symbol substitution task, heart rate 
and blood pressure) compared to active cannabis, which produced abuse-
related subjective effects as well as a range of other effects. [58] 
 
9. Therapeutic Applications and Extent of Therapeutic Use and 
Epidemiology of Medical Use 
Epilepsy 
The clinical use of CBD is most advanced in the treatment of epilepsy. In clinical 
trials, CBD has been demonstrated as an effective treatment for at least some forms of 
epilepsy, with one pure CBD product (Epidiolex®) currently in Phase III trials.  
The use of CBD for this purpose is based on a number of studies in animals dating 
back to the 1970s. [59] These studies demonstrated the anti-seizure activity of 
cannabidiol in a number of animal models. Based on this research, cannabidiol has 
been trialled in patients with epilepsy. 
In a very early small-scale double-blind placebo controlled trial, patients received 
either 200 mg CBD daily (4 patients) or placebo (5 patients) for a 3-month period, in 
addition to their habitual medication.  In the CBD group, two patients had no seizures 
for the entire 3-month period, one partially improved, and the fourth had no 
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improvement. No improvements were observed in the placebo group and no toxic 
effects were reported for either group. This study has a number of limitations, 
including the small sample size, unclear design as to blinding, and lack of definition 
of partial improvement. [60] 
In another study, 15 patients with “secondarily generalized epilepsy with temporal 
focus,” were randomly divided into two groups. In a double-blind procedure, each 
patient received 200-300 mg daily of CBD or placebo for up to four and a half months 
in combination with their existing prescribed antiepileptic medications (which were 
no longer effective in the control of their symptoms). CBD was tolerated in all 
patients, with no signs of toxicity or serious side effects. Of the eight participants in 
the CBD treatment group, four were reported to be almost free of seizure episodes 
throughout the trial, whereas three others showed partial clinical improvement. CBD 
was ineffective in one patient. In comparison, the clinical condition of seven placebo 
patients remained unchanged with one patient showing improvement.[61] 
There have also been some negative reports regarding the effectiveness of CBD. In a 
trial reported in 1986, a dose of CBD of 200–300 mg/day for a month resulted in no 
significant differences between the treatment and placebo groups. [62] Similarly, a 6-
month double blind study administering CBD 100 mg 3 times each day did not result 
in any changes in seizure frequency or improvement in cognition or behaviour. [63] 
The results of two trials examining the effects of CBD in patients with severe, 
intractable, childhood-onset, treatment-resistant epilepsy have been reported. The first 
was an open label study of 214 patients (aged 1–30 years) who were receiving stable 
doses of antiepileptic drugs before study entry. Patients were given oral cannabidiol, 
initially at 2–5 mg/kg per day, and then titrated until intolerance or to a maximum 
dose of 25 mg/kg or 50 mg/kg per day, dependent on study site. The primary measure 
was the percentage change in the frequency of seizures. In the CBD group, the median 
monthly frequency of motor seizures reduced from 30·0  at baseline to 15·8 over the 
12 week treatment period. The trial was also designed to assess safety, but the absence 
of a control group means that the results cannot be used to assess the likelihood of 
CBD producing particular effects. Adverse events reported in more than 10% of 
patients were somnolence, decreased appetite, diarrhoea, fatigue, and convulsion. Five 
(3%) patients discontinued treatment because of an adverse event. Serious adverse 
events were reported in 48 (30%) patients, of which 20 (12%) experienced severe 
adverse events possibly related to cannabidiol use, the most common of which was 
status epilepticus (n=9 [6%]). [64] 
The same research group recently reported the results of a controlled trial of CBD 
treatment for Dravet syndrome, a complex childhood epilepsy disorder that is 
associated with drug-resistant seizures and a high mortality rate. In a double-blind, 
placebo-controlled trial, 120 children and young adults with Dravet syndrome were 
randomly assigned to receive either cannabidiol oral solution (20 mg per kilogram per 
day) or placebo, in addition to standard antiepileptic treatment (a median of 3.0 
drugs). The authors reported that cannabidiol decreased the median frequency of 
convulsive seizures per month from 12.4 to 5.9, as compared with a decrease from 
14.9 to 14.1 with placebo. A small percentage (5%) of patients in the CBD group 
became seizure free as compared to zero in the placebo group. Adverse events that 
occurred more frequently in the cannabidiol group than in the placebo group included 
diarrhoea (31% vs 10%), loss of appetite (28% vs 5%) and somnolence (36% vs 
10%). Other adverse effects noticed were vomiting, fatigue, pyrexia and abnormal 
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results on liver-function tests. Adverse effects led to the withdrawal of eight patients 
in the cannabidiol group compared with one in the placebo group.[65]  
It has been suggested that some of the adverse effects of cannabidiol observed in the 
clinical studies may relate to interactions with other antiepileptic drugs. For example, 
a recent study evaluated thirteen subjects with refractory epilepsy concomitantly 
taking clobazam and CBD. Nine of 13 subjects had a >50% decrease in seizures, 
corresponding to a responder rate of 70%. Side effects were reported in 10 (77%) of 
the 13 subjects, but were alleviated with clobazam dose reduction. All subjects 
tolerated CBD well. [66]  
It has been suggested that cannabidiol (as Epidiolex) is likely to be submitted for 
regulatory approval by GW Pharmaceuticals for epilepsy treatment in 2017 following 
the successful outcomes reported in treatment of Dravet syndrome. 
Other indications 
There is also evidence that CBD may be a useful treatment for a number of other 
medical conditions.  However, this research is considerably less advanced than for 
treatment of epilepsy. For most indications, there is only pre-clinical evidence, while 
for some there is a combination of pre-clinical and limited clinical evidence. The 
range of conditions for which CBD has been assessed is diverse, consistent with its 
neuroprotective, antiepileptic, hypoxia-ischemia, anxiolytic, antipsychotic, analgesic, 
anti-inflammatory, anti-asthmatic, and antitumor properties.[37, 50, 67] The evidence 
for CBD’s various therapeutic applications was recently reviewed by Pisanti et al 
(2017), refer to Table 1.   
Another possible therapeutic application which has been investigated is the use of 
CBD to treat drug addiction. A recent systematic review concluded that there were a 
limited number of preclinical studies which suggest that CBD may have therapeutic 
properties on opioid, cocaine, and psychostimulant addiction, and some preliminary 
data suggest that it may be beneficial in cannabis and tobacco addiction in humans. 
However, considerably more research is required to evaluate CBD as a potential 
treatment. [68] 
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Table 1. Overview of diseases for which CBD may have therapeutic benefits taken from 
Pisanti et al (2017) [69] 
Disease Effects 
Alzheimer's disease Antinflammatory, antioxidant, antiapoptotic in in vitro and in vivo models 
of Aβ-evoked neuroinflammatory and neurodegenerative responses. 
Parkinson's disease Attenuation of the dopaminergic impairment in vivo; neuroprotection; 
improvement of psychiatric rating and reduction of agitation, nightmare 
and aggressive behaviour in patients. 
Multiple sclerosis Improved signs of EAE in mice, antinflammatory and immunomodulatory 
properties. 
Huntington's 
disease 
Neuroprotective and antioxidant in mice transgenic models; no significant 
clinically important differences in patients. 
Hypoxia-ischemia 
injury 
Short term neuroprotective effects; inhibition of excitotoxicity, oxidative 
stress and inflammation in vitro and in rodent models. 
Pain 
 
Analgesic effect in patients with neuropathic pain resistant to other 
treatments. 
Psychosis Attenuation of the behavioural and glial changes in animal models of 
schizophrenia; anti-psychotic properties on ketamine-induced symptoms 
Anxiety Reduction of muscular tension, restlessness, fatigue, problems in 
concentration, improvement of social interactions in rodent models of 
anxiety and stress; reduced social anxiety in patients. 
Depression Anti-depressant effect in genetic rodent model of depression. 
Cancer Antiproliferative and anti-invasive actions in a large range of cancer types; 
induction of autophagy-mediated cancer cell death; chemopreventive 
effects. 
Nausea Suppression of nausea and conditioned gaping in rats 
Inflammatory 
diseases 
Antinflammatory properties in several in vitro and in vivo models; 
inhibition of inflammatory cytokines and pathways. 
Rheumatoid 
arthritis 
Inhibition of TNF-α in an animal model 
Infection Activity against methicillin-resistant Staphylococcus aureus 
Inflammatory 
bowel and Crohn's 
diseases 
Inhibition of macrophage recruitment and TNF-α secretion in vivo and ex 
vivo; reduction in disease activity index in Crohn's patients. 
Cardiovascular 
diseases 
Reduced infarct size through anti-oxidant and anti-inflammatory 
properties in vitro and in vivo. 
Diabetic 
complications 
Attenuation of fibrosis and myocardial dysfunction 
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10. Listing on the WHO Model List of Essential Medicines 
Cannabidiol is not listed on the WHO Model List of Essential Medicines (20th List) or 
the WHO Model List of Essential Medicines for Children (6th List).[70] 
 
11. Marketing Authorizations (as a Medicinal Product) 
CBD is present in nabiximols (Sativex®) which is marketed by GW Pharmaceuticals 
in a number of countries. [71] As nabiximols also contains an equal amount of THC, 
it will be covered in a separate ECDD review.   
 
There are no currently authorized pure CBD products. However, there are several in 
development including Epidiolex® and Arvisol®.  
 
Epidiolex® is a liquid formulation of pure plant-derived CBD. It is produced by GW 
Pharmaceuticals and has shown positive results in phase 3 trials for Dravet and 
Lennox-Gastaut syndromes which are both treatment resistant seizure disorders.  The 
published results related to this therapeutic application are covered in Section 9: 
Therapeutic Applications. [72], [73] 
 
Arvisol® is an oral tablet containing pure CBD. It has been developed by Echo 
Pharmaceuticals in the Netherlands and is intended to be registered in the treatment of 
disorders such as schizophrenia and epilepsy. Arvisol® is still undergoing Phase I 
clinical trials and is not yet available as a medicinal product. [74] 
 
In 2015, the US Food and Drug Administration (FDA) granted GW Pharmaceuticals 
Fast Track designation for intravenous CBD to treat Neonatal Hypoxic-Ischemic 
Encephalopathy (NHIE).[75] The European Commission also granted orphan 
designation (EU/3/15/1520) for cannabidiol to be used in the treatment of perinatal 
asphyxia.[76] NHIE and Perinatal Asphyxia are forms of acute or sub-acute brain 
injury due to asphyxia caused during the birth process and resulting from deprivation 
of oxygen during birth (hypoxia). Currently there are no other treatments available for 
these conditions, but there is evidence of the effectiveness of cannabidiol in animal 
models. [77] 
 
12. Industrial Use 
Pure CBD has no legitimate industrial uses.  
 
13. Non-Medical Use, Abuse and Dependence 
At present, there are no case reports of abuse or dependence relating to the use of pure 
CBD. There are also no published statistics on non-medical use of pure CBD.  
 
There is unsanctioned medical use of CBD based products. These are produced from 
high CBD content plants and distributed in a variety of forms, including oils and 
capsules. These products are sold online as unapproved treatments for a variety of 
disorders including epilepsy, cancer, AIDS/HIV, anxiety, arthritis, pain, and post-
traumatic stress disorder (PTSD). Additionally, CBD is being used in skin and beauty 
products such as shampoos and skin creams.[78, 79] Also see Annex 1: Report on 
WHO questionnaire for review of psychoactive substances. 
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14. Nature and Magnitude of Public Health Problems Related to Misuse, 
Abuse and Dependence 
At present no public health problems (e.g. driving under the influence of drugs cases, 
comorbidities) have been associated with the use of pure CBD.  
 
Also refer to Annex 1: Report on WHO questionnaire for review of psychoactive 
substances. 
 
15. Licit Production, Consumption and International Trade 
Licit production of CBD for medical purposes is described in Section 11. Also refer to 
Annex 1: Report on WHO questionnaire for review of psychoactive substances. 
 
16. Illicit Manufacture and Traffic and Related Information 
There are no published statistics (e.g. country data on seizures of illicit CBD) 
currently available. Refer to Annex 1: Report on WHO questionnaire for review of 
psychoactive substances. 
 
17. Current International Controls and Their Impact 
Cannabidiol is not listed in the schedules of the 1961, 1971 or 1988 United Nations 
International Drug Control Conventions.[80]  
 
However, cannabidiol is being produced for pharmaceutical purposes as an extract of 
cannabis by GW Pharmaceuticals. Cannabidiol that is produced as an extract of 
cannabis is currently included in Schedule I of the 1961 Convention.  
 
18. Current and Past National Controls 
United Kingdom: A statement was issued by the Medicines and Healthcare products 
Regulatory Agency  (MHRA) in 2016 that products containing CBD used for medical 
purposes are considered as a medicine subject to standard licensing requirements. [81] 
United States: CBD is one of many cannabinoids present in cannabis, and as such is in 
schedule I of the Controlled Substances Act. However in December 2015, the FDA 
eased the regulatory requirements to allow researchers to conduct CBD trials. The 
Drug Enforcement Agency (DEA) stated that these modifications are intended to 
streamline the research process regarding CBD’s possible medicinal value and help 
foster ongoing scientific studies. [82] 
 
Canada: CBD is specifically listed in ‘Cannabis, its preparations and derivatives’ as a 
controlled substance listed in Schedule II Controlled Drugs and Substances Act. 
However, in 2016 Canada’s Access to Cannabis for Medical Purposes Regulations 
came into effect. These regulations improve access to cannabis used for medicinal 
purposes, including CBD. [83] 
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Australia:  In 2015, CBD in preparations for therapeutic use containing 2 per cent or 
less of other cannabinoids found in cannabis was placed in Schedule 4 as a 
‘Prescription Only Medicine OR Prescription Animal Remedy’. Previous to this it 
was captured in Schedule 9 as a prohibited substance.[84]  
 
New Zealand CBD is a controlled drug, however many of the restrictions currently 
imposed by the regulations will be removed by the end of 2017. The changes will 
mean that CBD products, where the level of other naturally occurring cannabinoids is 
less than 2% of the cannabinoid content, will be easier to access for medical use. [85] 
 
Switzerland: CBD is not subject to the Narcotics Act because it does not produce a 
psychoactive effect. It is still subject to standard Swiss legislation. [86] 
  
Also refer to Annex 1: Report on WHO questionnaire for review of psychoactive 
substances. 
 
19. Other Medical and Scientific Matters Relevant for a Recommendation 
on the Scheduling of the Substance 
None 
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Annex 1: Report on WHO Questionnaire for Review of 
Psychoactive Substances for the 39th ECDD: Evaluation of 
Cannabidiol 
 
Please refer to separate Annex 1 document published on ECDD website 
